Permanently Block Cancer Development Factor
- Researchers have developed a novel screening technology capable of identifying peptides that can permanently block a crucial factor in cancer development.
- Scientists at Bath University in England have identified peptides that can irreversibly deactivate a key protein implicated in cancer.
- The team has engineered the first irreversible peptide inhibitors to target the CJun protein, a important contributor to cancer progression.
Table of Contents
- New Peptide Technology Shows Promise in Blocking Cancer-Related Protein
- New Peptide Technology: A Breakthrough in cancer Treatment?
- What is the new peptide technology for cancer?
- What are peptide inhibitors, and how do they work?
- Which protein is being targeted, and why is it vital?
- What makes this peptide technology different from previous attempts to treat cancer?
- How does the new screening technology work?
- What is the Transcription blocks Assay (TBS)?
- What are the potential benefits of this new technology?
- What are the next steps for this research?
- Summary of Key Features:
Researchers have developed a novel screening technology capable of identifying peptides that can permanently block a crucial factor in cancer development. This breakthrough offers a potential new avenue for cancer therapies, notably for proteins that have proven challenging too target with conventional drugs.
Irreversible Peptide Inhibitors Target Key Protein
Scientists at Bath University in England have identified peptides that can irreversibly deactivate a key protein implicated in cancer. Their new screening technology allows for the identification of effective molecules within cells.
The team has engineered the first irreversible peptide inhibitors to target the CJun protein, a important contributor to cancer progression. This protein was previously considered untreatable.
Transcript Factors and the Promise of Peptides
Transcript factors,proteins that regulate gene expression,are known to play a critical role in cancer development. While many attempts have been made to develop drugs that block these proteins, most have been unsuccessful.Recent research has focused on peptides – short chains of amino acids – as a potential solution for targeting these difficult-to-reach proteins.
Advanced Screening Method Developed
The Bath University team has developed an advanced method for discovering peptides that selectively and irreversibly target transcript factors within cells. This technique has enabled them to block the activity of CJun, a transcript factor associated with the uncontrolled proliferation of cancer cells.
Transcription Blocks Assay (TBS)
The research, published in the journal Advanced Science, utilizes an innovative drug revelation platform called the Transcription Blocks Assay (TBS). This platform facilitates the screening of a large number of peptides to identify those capable of disabling transcription factors involved in cancer.
Previously, the team had identified reversible inhibitors of the CJun protein. However, this new study has led to the discovery of peptides that bind irreversibly to the protein, permanently blocking its function.
How the Inhibitor Works
The CJun protein consists of two identical halves that bind to DNA to alter gene expression. In cancer, CJun can become hyperactive, contributing to uncontrolled cell growth. The researchers designed a peptide inhibitor that attaches to one half of the CJun protein, preventing it from forming pairs and binding to DNA.
After creating an inhibitor that binds to the transcript factor, the researchers modified it to bind irreversibly to cancer cells.
According to Dr. Andy Brennan, of Bath University, “The inhibitor works like a harpoon that attaches to the target and doesn’t release – it is firmly linked to CJun and prevents it from interacting with the DNA. In the past, we have discovered reversible inhibitors, but this is the first peptide inhibitor that irreversibly blocks a transcript factor.”
The inhibitors have been tested directly in cancer cells, ensuring that onyl non-toxic peptides are identified.
TBS Testing and Screening
In the tests, researchers introduced specific DNA sequences for cjun into essential genes of cells grown in the laboratory. When CJun binds to this gene, it disrupts normal cell function, leading to cell death. Conversely, if CJun is blocked by the peptide inhibitor, gene activity is restored, and the cells survive.
Professor Jody Mason,a specialist at Bath and Scientific Director,said that “Many candidate molecules for drug status prove toxic or unable to penetrate cancer cells. But our platform allows the activity of peptides directly inside the cell, avoiding the many obstacles associated with medicines based on small molecules or antibodies.”
Mason added that this method verifies whether the inhibitor functions in a real cellular surroundings, where other proteins can interfere with peptide activity, while also evaluating toxicity.
Future Research
The researchers are optimistic that this technology will lead to the discovery of new cancer treatment candidates, including those for proteins previously considered undruggable.
Having demonstrated that the discovered inhibitors can enter cancer cells and selectively act on the target, the research team is now preparing to test their effectiveness in preclinical cancer models.
New Peptide Technology: A Breakthrough in cancer Treatment?
What is the new peptide technology for cancer?
Researchers have developed a novel screening technology that identifies peptides. These peptides can permanently block a crucial protein involved in cancer development, offering a potential new approach to cancer therapies. This technology is notably promising for targeting proteins that have been arduous to treat with conventional drugs.
What are peptide inhibitors, and how do they work?
Peptide inhibitors are short chains of amino acids designed to target and disrupt the function of specific proteins. In this case, the focus is on irreversible peptide inhibitors that target a key protein implicated in cancer. The technology developed by scientists at Bath University in England allows for the identification of effective molecules within cells.
The inhibitor works by attaching to one half of the CJun protein,a transcript factor associated with the uncontrolled proliferation of cancer cells,preventing it from pairing and binding to DNA. This mechanism effectively blocks the CJun protein, preventing it from interacting with DNA and altering gene expression, which is critical for the progression of cancer.
Which protein is being targeted, and why is it vital?
The researchers are targeting the CJun protein, a transcript factor playing a crucial role in cancer development. The CJun protein was previously considered essentially untreatable. In cancer cells, CJun can become hyperactive, contributing to uncontrolled cell growth.
What makes this peptide technology different from previous attempts to treat cancer?
Unlike many previous attempts to develop drugs that block transcript factors, this new technology utilizes peptides — short chains of amino acids. Moreover, the technology has produced irreversible peptide inhibitors. The researchers have engineered the first irreversible peptide inhibitors to target the CJun protein.
According to Dr. Andy Brennan of Bath University, “The inhibitor works like a harpoon that attaches to the target and doesn’t release – it is indeed firmly linked to CJun and prevents it from interacting with the DNA.”
How does the new screening technology work?
The team at Bath University developed an advanced method to discover peptides that selectively and irreversibly target transcript factors within cells. This advanced screening method utilizes an innovative drug revelation platform called the Transcription Blocks Assay (TBS). The TBS platform facilitates the screening of a large number of peptides to identify those capable of disabling transcription factors involved in cancer.
The research team introduced specific DNA sequences (for cjun) into essential genes of cells grown in the laboratory during testing.
What is the Transcription blocks Assay (TBS)?
the Transcription Blocks Assay (TBS) is an innovative drug revelation platform developed by the researchers. it facilitates the screening of a large number of peptides to identify those that can disable transcription factors involved in cancer.
What are the potential benefits of this new technology?
The researchers are optimistic that this technology will lead to the discovery of new cancer treatment candidates. In particular, it may offer treatments for proteins that were previously considered “undruggable.” The technology allows the peptides’ activity to be assessed directly inside the cell, avoiding obstacles related to small molecule or antibody-based medicines.
What are the next steps for this research?
Having demonstrated that the discovered inhibitors can enter cancer cells and selectively act on the target, the research team is now preparing to test their effectiveness in preclinical cancer models. This will involve further study to determine the efficacy and safety of these peptide inhibitors.
Summary of Key Features:
| Feature | Description |
| :—————————- | :——————————————————————————————————————————————— |
| Target | CJun protein (transcript factor) in cancer cells |
| Mechanism | Irreversible peptide inhibitors that attach to CJun and prevent DNA binding. |
| Screening Method | Transcription Blocks Assay (TBS), enables screening of many peptides within cells. |
| Key Advantage | The peptide inhibitors are designed to bind irreversibly, providing long-lasting effects. |
| Development Team | Scientists at Bath University in England. |
| Current Status | Inhibitors have been tested directly in cancer cells and are now being prepared for testing in preclinical cancer models. |